Treatment for Alzheimer disease by CpG with RVG

Research Project

Project/Area Number	26670441
Research Category	Grant-in-Aid for Challenging Exploratory Research
Allocation Type	Multi-year Fund
Research Field	Neurology
Research Institution	Nagoya University
Principal Investigator	Mizuno Tetsuya 名古屋大学, 環境医学研究所, 客員准教授 (70335008)
Project Period (FY)	2014-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000) Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywords	ミクログリア / アルツハイマー病 / 機能性ペプチド核酸 / RVG-CPG / 脳移行性ペプチド / CpG
Outline of Final Research Achievements	Soluble oligomeric amyloid beta (oAb) 1-42 causes synaptic dysfunction and neuronal injury in Alzheimer’s disease (AD). Microglia are involved in AD pathology. Microglia activated with unmethylated DNA CpG motif (CpG), a ligand for toll-like receptor 9, attenuated oAb neurotoxicity. In this study, we developed CpG with a specific target peptide for the brains; ravies virus glycoprotein (RVG). Intraperitoneal (IP) administration of CpG with RVG ameliorated the impairment of associative learning in APP/PS1 mouse model of AD. We propose that CpG with RVG may be an effective therapeutic strategy for inhibiting oAbeta 1-42 neurotoxicity in AD.

Report

(3 results)